Abstract #1118
Non-Invasive Imaging Biomarkers of Tumor Response to XL184 Therapy
Benjamin A Hoff 1 , Jean-Christophe Brisset 2 , Stefanie Galbn 3 , Craig J Galbn 1 , and Brian D Ross 1
1
Radiology, University of Michigan, Ann
Arbor, MI, United States,
2
New
York University Langone, NY, United States,
3
Radiation
Oncology, University of Michigan, MI, United States
Clinical response criteria (RECIST 1.1) considers boney
metastases measuring >10mm without soft tissue
involvement as unmeasurable. The clinical need for
accurate therapeutic response measures is more pressing
with the introduction of targeted therapies into
standard of treatment. XL184 is a novel tyrosine kinase
inhibitor that exhibits activity against mainly MET and
VEGFR-2.1 We evaluated DW-MRI and CT pre- and
post-therapy on a mouse model of bone-metastatic
prostate cancer to assess early treatment response to
this therapy. The therapeutic effect of XL184 was
observed via several readouts, with mean tumor ADC
increasing significantly over controls by day 3
post-therapy.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Click here for more information on becoming a member.
